NASDAQ:LGNDLigand Pharmaceuticals Stock Price, Forecast & News

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LGND shares have increased by 23.7% and is now trading at $113.59. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ligand Pharmaceuticals.

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Ligand Pharmaceuticals.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.66 by $0.23. The biotechnology company had revenue of $33.16 million for the quarter, compared to analyst estimates of $26.70 million. Ligand Pharmaceuticals had a negative net margin of 55.63% and a positive return on equity of 3.68%. The company's revenue for the quarter was down 23.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.16 EPS. View Ligand Pharmaceuticals' earnings history.

Ligand Pharmaceuticals updated its FY20 earnings guidance on Wednesday, May, 6th. The company provided earnings per share guidance of approx $3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.59. The company issued revenue guidance of approx $140 million, compared to the consensus revenue estimate of $131.03 million.

6 Wall Street analysts have issued 12 month price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $132.00 to $229.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $169.00 in the next year. This suggests a possible upside of 48.8% from the stock's current price. View analysts' price targets for Ligand Pharmaceuticals.

Media stories about LGND stock have trended very negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Ligand Pharmaceuticals.

Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Netflix (NFLX), Intel (INTC), Gilead Sciences (GILD), Cisco Systems (CSCO) and Illumina (ILMN).

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Woodstock Corp (0.44%) and Envestnet Asset Management Inc. (0.13%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Sunil Patel and Todd C Davis. View institutional ownership trends for Ligand Pharmaceuticals.

LGND stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Woodstock Corp. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins, Matthew W Foehr, and Sunil Patel. View insider buying and selling activity for Ligand Pharmaceuticals.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LGND stock can currently be purchased for approximately $113.59.

Ligand Pharmaceuticals has a market capitalization of $1.82 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.

The official website for Ligand Pharmaceuticals is www.ligand.com.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]